Obesity is a central driver of advanced chronic liver disease, fueling the rise of metabolic dysfunction-associated steatotic liver disease (MASLD) and its inflammatory form, MASH. These conditions are now leading causes of cirrhosis, liver cancer, and transplants.
Higher BMI worsens outcomes across all liver diseases-patients face up to three times greater risk of clinical decline. The damage stems from inflamed fat tissue releasing fatty acids and inflammatory signals that trigger liver fat buildup, injury, and fibrosis.
Weight loss remains the most effective intervention: 5% improves metabolism; 10% or more reduces liver inflammation and scarring. But sustained loss is rare with lifestyle changes alone.
New GLP-1 receptor agonists-part of incretin-based therapies-deliver 5-10% weight loss while improving liver fat and metabolic health. Early data suggest they may resolve MASH, though fibrosis reversal takes longer. Bariatric surgery offers durable results for up to 20 years but carries risks in advanced liver disease.
Long-term adherence is critical. Obesity’s relapsing nature means combination strategies-drugs, surgery, and lifestyle-will likely define future care.